We're delighted that abiraterone will now be available to men
regardless of where they live in the UK. Initially the drug was
rejected for use on the NHS, but in June the National Institute for
Health and Clinical Excellence (NICE) reversed its draft
decision for England and Wales, the Health Department in Northern
Ireland endorsed this decision, and now the Scottish Medicines
Consortium (SMC) has followed suit.
This is great news for men with advanced prostate cancer and a
major victory for Prostate Cancer UK's campaign.
Thank you to all our supporters, men with prostate cancer
and their families, health professionals and politicians who helped
with this campaign.
Autumn 2012 update
For men who haven’t had chemotherapy, the manufacturer
has now applied for a licence which, if granted, could lead to
these men being able to receive abiraterone. As soon as we hear the
decision we will post more information on these pages.